By DAN MCGOWAN Writer/Reporter, Inside Indiana Business A potential rheumatoid arthritis treatment being co-developed by Indianapolis-based Eli Lilly and Co. and Incyte Corp. continues to return positive results in late-stage testing. In a recent phase-three global study, Lilly says baricitinib met its primary endpoint. The results have been published in the New England Journal of Medicine. Lilly’s …read more.

By ANDY OBER Assistant Managing Editor InsideIndianaBusiness INDIANAPOLIS — The U.S. Food and Drug Administration has approved a type 2 diabetes treatment from Indianapolis-based Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. Synjardy was also approved earlier this year by the European Medicines Agency. Lilly says Synjardy is the third product containing the medicine epagliflozin to …read more.

Eli Lilly and Company (NYSE: LLY) and Sarah Cannon Research Institute (SCRI) today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.

Companion Medical, Inc, San Diego-based medical device company developing advanced systems for delivery of insulin and other drugs, has announced the completion of a series B financing, led by an investment from Eli Lilly and Company. “We are very excited to have Lilly as the lead investor in our series B financing,” said Sean Saint, …read more.

Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportion of patients achieving an ACR 20 response. ACR 20 is a standard assessment that represents a 20 percent reduction in disease signs …read more.

Eli Lilly and Company and Innovent Biologics, Inc., announced one of the largest biotech drug development collaborations in China thus far today in Beijing. Under the agreement, Lilly and Innovent will collaborate to develop and potentially commercialize at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, …read more.

Students from Indiana University School of Medicine are getting a first-hand look at how new medicines are discovered. Through a partnership with Lilly USA, third- and fourth-year medical students from IU School of Medicine are learning about drug development and how the many physicians working at Lilly play different and important roles in bringing new …read more.

Eli Lilly and Company (NYSE: LLY) yesterday announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly’s Elanco as a global leader in the animal health industry. The transaction, first announced on April 22, has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. As part of the approval, certain …read more.

Eli Lilly and Company (NYSE: LLY) has received its third US Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). Specifically, CYRAMZA is now also indicated in combination with docetaxel, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or …read more.

Eli Lilly and Company (NYSE: LLY) and AstraZeneca yesterday announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. AZD3293, also known as LY3314814, has been shown in Phase I studies to reduce levels …read more.

INDIANAPOLIS – In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are changing the operational and financial structure of their diabetes alliance in certain countries. Under the revised agreement, 17 countries representing more than 90 percent of …read more.

Eli Lilly and Company (NYSE: LLY) today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer’s disease. However, a pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline …read more.